speedy/RINGO cell cycle regulator family member E7, pseudogeneGenealiases: []
Q-omics provides the consensus-scored SPDYE7P profile across patient tissues and cancer cell-line models. SPDYE7P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, SPDYE7P is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, SPDYE7P RNA expression shows 8,232 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, KICH, and UVM as cancer lineages where SPDYE7P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPDYE7P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPDYE7P survival associations across molecular data types. SPDYE7P RNA expression shows survival associations in the most cancer types (14), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPDYE7P RNA expression–survival associations across cancer types. High SPDYE7P expression shows unfavorable associations in PAAD, UVM, LUSC, SARC, ACC and KICH. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify PAAD as the clearest survival context for SPDYE7P RNA expression.
This table summarizes SPDYE7P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SPDYE7P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPDYE7P shows lower tumor expression in KICH and higher tumor expression in LUSC. The KICH box plot shows higher SPDYE7P RNA expression in normal versus tumor tissue (log2 FC = −0.054, t-test p = .001).
This table shows molecular features associated with SPDYE7P in patient tissues and cancer cell lines. In patient samples, SPDYE7P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPDYE7P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
